Strategy for the Prediction and Selection of Drug Substance Salt Forms - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Strategy for the Prediction and Selection of Drug Substance Salt Forms
Through consideration of the ionic equilibria of acids and bases, one may readily calculate the formation constant of a salt species solely on the basis of knowledge of the pKA value of the acid and the pKB value of the base.


Pharmaceutical Technology


In Equation 2, the quantities in square brackets represent the molar concentrations of the various species, and the γ quantities are the activity coefficients of those species. For an acid capable of ionizing into a univalent anion, γH + and γA will be approximately equal, and γHA can be approximated as unity, so that the concentration-based equilibrium constant expression can be simply written as:



For weak acids, the magnitude of K A is very small, and therefore, the resulting H3O+ and A ions will be produced in small amounts. Under those conditions, both γH+ and γA will be approximately equal to one, facilitating the approximation that the thermodynamic equilibrium constant, K, equals the concentration-based ionization constant, K A . Making use of the Sørensen scale, one can define the pK A of a weak acid as:



A strong acid is defined as a substance that reacts completely with water so that the acid ionization constant defined in Equation 2 or 3 is very large. This situation can only be achieved if the conjugate base of the strong acid is very weak. A weak acid will be characterized by an acid ionization constant that is considerably less than unity, so that the position of equilibrium in the reaction represented in Equation 1 favors the existence of nonionized free acid. The implication of these properties is that the conjugate base of the weak acid must be moderately strong.

A discussion of the ionic equilibria associated with basic substances exactly parallels that just developed for acidic substances. A base is a substance capable of accepting a proton donated by another substance, such as water:



The basic substance (B) that originally accepted the proton becomes the conjugate acid (BH+ ) of that substance, since the conjugate acid could conceivably donate a proton to an even stronger base than the original substance. The concentration-based ionization constant expression corresponding to Equation 5 is:



and pK B is defined as:



A strong base is a substance that reacts completely with water, so the base ionization constant defined in Equation 6 is effectively infinite. This situation can only be realized if the conjugate acid of the strong base is very weak. Since the conjugate acid of a weak base will be moderately strong, the base ionization constant will be considerably less than one, and the position of equilibrium in the reaction represented in Equation 5 will favor the existence of a nonionized free base.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here